<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011305</url>
  </required_header>
  <id_info>
    <org_study_id>SARO.20.002</org_study_id>
    <nct_id>NCT05011305</nct_id>
  </id_info>
  <brief_title>Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis</brief_title>
  <acronym>NASH</acronym>
  <official_title>A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zydus Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zydus Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to&#xD;
      Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic&#xD;
      Steatohepatitis and Fibrosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>240 subjects randomized in a 1:1:1 ratio to Saroglitazar 2 mg, Saroglitazar 4 mg or Placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind Masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of steatohepatitis with no worsening of fibrosis</measure>
    <time_frame>76 Weeks/EOT</time_frame>
    <description>Resolution of steatohepatitis is defined as absent fatty liver disease or isolated or simple steatosis without steatohepatitis and a NAS of 0-1 for inflammation, 0 for ballooning, and any value for Steatosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver fibrosis with no increase in NAS for ballooning, inflammation or steatosis</measure>
    <time_frame>Week 76/EOT</time_frame>
    <description>Proportion of subjects achieving improvement in liver fibrosis (reduction of at least one stage) with no increase in NAS for ballooning, inflammation or steatosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 points improvement in NAS</measure>
    <time_frame>Week 76/EOT</time_frame>
    <description>Proportion of subjects with at least 2 points improvement in NAS at Week 76/EOT with at least 1-point improvement in either ballooning or inflammation and no worsening of liver fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in steatosis, ballooning, inflammation and fibrosis from liver biopsy</measure>
    <time_frame>Week 76/EOT</time_frame>
    <description>Proportion of subjects with ≥1 point improvement in steatosis, ballooning, inflammation and fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in SAF score on liver biopsy</measure>
    <time_frame>Week 76/EOT</time_frame>
    <description>Proportion of subjects with decrease in SAF score ≥2 combining hepatocellular inflammation and ballooning without worsening of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological score changes in steatosis, ballooning, inflammation, and fibrosis</measure>
    <time_frame>Week 76/EOT</time_frame>
    <description>Change from baseline in steatosis, ballooning, inflammation, and fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver enzyme parameters including (ALT, AST, ALP, GGT, total bilirubin, albumin)</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in liver enzyme parameters (ALT, AST, ALP, GGT, total bilirubin, albumin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-invasive markers of steatosis</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in non-invasive markers of steatosis (Enhanced Liver Fibrosis [ELF] test, Fibrosis 4 [FIB 4], APRI [AST to Platelet Ratio Index], NFS [NAFLD Fibrosis Score], PRO-C3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in n lipid parameters including (TG, LDLC, TC, HDL-C, non-HDL-C, VLDL-C</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in lipid parameters (TG, LDLC, TC, HDL-C, non-HDL-C, VLDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (any change from baseline)</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin resistance marker, HOMA-IR</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in insulin resistance marker (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers including (CK-18 [M30], IL-6, CRP)</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in inflammatory markers (CK-18 [M30], IL-6, CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucose homeostasis markers including (HbA1c, FPG)</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in glucose homeostasis markers (HbA1c, FPG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in non-invasive markers of fibrosis</measure>
    <time_frame>Week 52 and Week 76/EOT</time_frame>
    <description>Change from baseline in non-invasive markers of fibrosis (Enhanced Liver Fibrosis [ELF] test, Fibrosis 4 [FIB 4], APRI [AST to Platelet Ratio Index], NFS [NAFLD Fibrosis Score], PRO-C3)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Saroglitazar Magnesium 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar Magnesium 2 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saroglitazar Magnesium 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saroglitazar Magnesium 4 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 2 mg</intervention_name>
    <description>Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
    <arm_group_label>Saroglitazar Magnesium 2 mg</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saroglitazar Magnesium 4 mg</intervention_name>
    <description>Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
    <arm_group_label>Saroglitazar Magnesium 4 mg</arm_group_label>
    <other_name>Investigational Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment (76 weeks).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Comparator Agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, between 18 and 75 years of age, both inclusive at screening.&#xD;
&#xD;
          -  BMI ≤45 kg/m²&#xD;
&#xD;
          -  Histological confirmation of NASH with liver fibrosis by central pathologist on a&#xD;
             diagnostic liver biopsy with a NAS ≥5 with at least one-point score in each of the&#xD;
             three components of the NAFLD activity score [NAS] (steatosis scored 0-3, ballooning&#xD;
             degeneration scored 0-2, and lobular inflammation scored 0-3) and NASH by pattern&#xD;
             recognition Note: The biopsy must not have been performed more than 24 weeks before&#xD;
             randomization.&#xD;
&#xD;
          -  The subjects must have a stable body weight (no more than 5% change) between the time&#xD;
             of biopsy and randomization.&#xD;
&#xD;
          -  Fibrosis stage 2 and 3, according to the NASH CRN fibrosis staging, reported by&#xD;
             central pathologist.&#xD;
&#xD;
          -  If the subjects have type 2 diabetes mellitus, then it must be moderately controlled&#xD;
             with HbA1c ≤ 9% and on a stable dose of permitted anti-diabetic medication for at&#xD;
             least 90 days before screening.&#xD;
&#xD;
          -  If the subjects are taking vitamin E &gt; 400 IU/day, then it must be on a stable dose&#xD;
             for at least 24 weeks prior to screening or, if a historical biopsy is used, at least&#xD;
             24 weeks prior to baseline liver biopsy until time of screening.&#xD;
&#xD;
          -  Must provide written informed consent and agree to comply with the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of &gt;3 units of alcohol per day (&gt;21 units per week) if male and &gt;2 units&#xD;
             of alcohol per day (&gt;14 units per week) if female for at least 12 consecutive weeks&#xD;
             within 5 years before screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or&#xD;
             1 ounce of spirits/hard liquor)&#xD;
&#xD;
          -  History or presence of other concomitant liver diseases at screening:&#xD;
&#xD;
               1. Chronic hepatitis B (HBV) or hepatitis C virus (HCV) infection (However, If the&#xD;
                  subject has been treated for the HCV infection and has been cured at least 5&#xD;
                  years from screening, such subjects can be enrolled in the study)&#xD;
&#xD;
               2. Primary biliary cholangitis (PBC)&#xD;
&#xD;
               3. Primary sclerosing cholangitis (PSC)&#xD;
&#xD;
               4. Definite autoimmune liver disease or overlap syndrome&#xD;
&#xD;
               5. Alcoholic liver disease&#xD;
&#xD;
               6. Hemochromatosis&#xD;
&#xD;
               7. Wilsons disease&#xD;
&#xD;
               8. Alpha-1 antitrypsin deficiency&#xD;
&#xD;
          -  Subject with known cirrhosis, either based on histology, clinical criteria or any&#xD;
             non-invasive diagnostic modality, within 24 weeks prior to the randomization.&#xD;
&#xD;
          -  Evidence of portal hypertension (low platelet count, esophageal varices, ascites,&#xD;
             history of hepatic encephalopathy, splenomegaly) at screening.&#xD;
&#xD;
          -  Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium glucose&#xD;
             cotransporter- 2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 inhibitors (gliptins)&#xD;
             unless stable for 90 days prior to screening or, if a historical biopsy is used, from&#xD;
             90 days prior to baseline liver biopsy until time of screening.&#xD;
&#xD;
          -  Use of concurrent medications prior to screening including:&#xD;
&#xD;
               1. Anti-NASH therapy(s) including S-adenosyl methionine (SAMe), ursodeoxycholic acid&#xD;
                  (UDCA), obeticholic acid and milk thistle in the period from 90 days prior to&#xD;
                  screening or, if a historical biopsy is used, from 90 days prior to baseline&#xD;
                  liver biopsy until time of screening.&#xD;
&#xD;
               2. Antidiabetic mediation which may impact NASH histology including&#xD;
                  thiazolidinediones (pioglitazone, rosiglitazone) in the period from 90 days prior&#xD;
                  to screening or, if a historical biopsy is used, from 90 days prior to baseline&#xD;
                  liver biopsy until time of screening.&#xD;
&#xD;
               3. Immune modulatory agents including anti-TNF-α therapies (infliximab, adalimumab,&#xD;
                  etanercept) or anti-integrin therapy (namixilab) in the period from 28 days prior&#xD;
                  to screening or if a historical biopsy is used from 28 days prior to baseline&#xD;
                  liver biopsy until time of screening.&#xD;
&#xD;
               4. Any treatment or anticipated initiation (intended use for more than 14&#xD;
                  consecutive days) of medications known to have an effect on steatosis (e.g.&#xD;
                  treatment with corticosteroids [topical and inhaled are allowed]), methotrexate,&#xD;
                  tamoxifen, valproic acid, amiodarone or tetracycline, estrogens in doses higher&#xD;
                  than used in oral contraceptives, vitamin A, L-asparaginase, valproate,&#xD;
                  chloroquine, or antiretroviral drugs in the period from 28 days prior to&#xD;
                  screening or, if a historical biopsy is used, from 28 days prior to baseline&#xD;
                  liver biopsy until time of screening.&#xD;
&#xD;
               5. Treatment with orlistat, zonisamide, topiramate, phentermine, lorcaserin,&#xD;
                  bupropion, or naltrexone alone, or in combination or any other medication, that&#xD;
                  could promote weight loss, in the opinion of the investigator, in the period from&#xD;
                  28 days prior to screening or if a historical biopsy is used from 28 days prior&#xD;
                  to baseline liver biopsy until time of screening.&#xD;
&#xD;
          -  Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin,&#xD;
             fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, Fenofibrate) in the 90&#xD;
             days preceding screening.&#xD;
&#xD;
          -  Use of drugs that are known CYP2C8 inhibitors/substrate in the 28 days preceding&#xD;
             screening.&#xD;
&#xD;
          -  History of liver transplant&#xD;
&#xD;
          -  Any weight reduction surgery in the 2 years prior to screening or planned during the&#xD;
             study (weight reduction surgery is disallowed during the study), and malabsorptive&#xD;
             weight loss surgery (Rouxen-Y or distal gastric bypass) at any time prior to&#xD;
             screening.&#xD;
&#xD;
        Note: Lap banding, if the band has been removed &gt;6 months before baseline liver biopsy, or&#xD;
        intragastric balloon, if the balloon has been removed &gt; 6 months before baseline liver&#xD;
        biopsy, is allowed.&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection within the six months prior to&#xD;
             screening that would potentially alter absorption and/or excretion of orally&#xD;
             administered drugs as judged by the investigator.&#xD;
&#xD;
          -  Unstable cardiovascular disease, including:&#xD;
&#xD;
               1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease) in&#xD;
                  the 90 days before screening and throughout the screening period; acute coronary&#xD;
                  syndrome in the 24 weeks before screening and throughout the screening period;&#xD;
&#xD;
               2. acute myocardial infarction in the 90 days before screening and throughout the&#xD;
                  screening period; or heart failure of New York Heart Association class (III -&#xD;
                  IV), worsening congestive heart failure, or coronary artery intervention, in the&#xD;
                  24 weeks before screening and throughout the screening period.&#xD;
&#xD;
               3. history of unstable cardiac dysrhythmias&#xD;
&#xD;
               4. uncontrolled hypertension at screening&#xD;
&#xD;
               5. stroke or transient ischemic attack in the 24 weeks before screening&#xD;
&#xD;
          -  History of myopathies or evidence of active muscle disease demonstrated by CPK ≥ 5&#xD;
             times ULN at screening.&#xD;
&#xD;
          -  Subjects whose ALT, AST, or ALP exceeds by more than 50% at Visit 2 reading compared&#xD;
             to Visit 1.&#xD;
&#xD;
        Note: If the ALT, AST or ALP values at Visit 2 exceed by more than 50% from Visit 1, then a&#xD;
        third value will be measured to assess for the trend. If the third value shows continued&#xD;
        increase ≥ 10%, then subject is considered ineligible for randomization.&#xD;
&#xD;
          -  Any of the following laboratory values at screening:&#xD;
&#xD;
               1. Hemoglobin &lt;9 g/dL&#xD;
&#xD;
               2. WBC count &lt;2.5 × 103/µL&#xD;
&#xD;
               3. Neutrophil count &lt;1.5 × 103/µL&#xD;
&#xD;
               4. Platelets &lt;140 × 103/µL&#xD;
&#xD;
               5. INR ≥ 1.3 (in the absence of anticoagulants)&#xD;
&#xD;
               6. Total bilirubin &gt; ULN except in Gilbert's syndrome. In subjects with known&#xD;
                  Gilbert's syndrome, direct bilirubin &gt; 2 x ULN&#xD;
&#xD;
               7. Albumin &lt;3.5 g/dL&#xD;
&#xD;
               8. eGFR &lt;60 mL/min/1.73 m2&#xD;
&#xD;
               9. ALP ≥ 2x ULN&#xD;
&#xD;
              10. ALT or AST ≥ 250 U/L&#xD;
&#xD;
          -  Participation in any other therapeutic clinical study and on active treatment in the&#xD;
             past 90 days of the screening.&#xD;
&#xD;
          -  History of benign or malignant bladder tumors, and/or hematuria or has current&#xD;
             hematuria except due to a urinary tract infection.&#xD;
&#xD;
          -  History of malignancy in the past 5 years and/or active neoplasm with the exception of&#xD;
             resolved superficial nonmelanoma skin cancer.&#xD;
&#xD;
          -  Known allergy, sensitivity or intolerance to the study drug, comparator or formulation&#xD;
             ingredients.&#xD;
&#xD;
          -  Pregnancy-related exclusions, including:&#xD;
&#xD;
               1. Pregnant/lactating female (including positive pregnancy test at screening)&#xD;
&#xD;
               2. Fertile women and men, UNLESS using effective contraceptive methods (such as an&#xD;
                  intrauterine device or other mechanical contraception method with condom or&#xD;
                  diaphragm and spermicide or proper use of hormonal contraceptives that inhibit&#xD;
                  ovulation) throughout the study. For male subjects, contraception measures&#xD;
                  (condom and spermicide) must be taken during the study, either by the male&#xD;
                  participant or his female partner.&#xD;
&#xD;
        (Note: Enrolled females otherwise must be surgically sterilized for at least 24 weeks&#xD;
        before screening; postmenopausal, defined as 52 weeks with no menses without an alternative&#xD;
        medical cause; or following sexual abstinence.)&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions that would make&#xD;
             the subject, in the opinion of the investigator, unsuitable for the study (such as&#xD;
             poorly controlled psychiatric disease, HIV, coronary artery disease or active&#xD;
             gastrointestinal conditions that might interfere with drug absorption)&#xD;
&#xD;
          -  Receiving an elemental diet or parenteral nutrition.&#xD;
&#xD;
          -  Chronic pancreatitis or pancreatic insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deven V. Parmar, MD, FCP</last_name>
    <role>Study Director</role>
    <affiliation>Zydus Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deven Parmar, MD</last_name>
    <phone>+91-9974252975</phone>
    <email>dparmar@zydustherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Bainbridge, JD</last_name>
    <phone>1-609-559-0760</phone>
    <email>jbainbridge@zydustherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zydus US014</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zydus US012</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zydus US003</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zydus US004</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zydus US011</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Saroglitazar Magnesium</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <keyword>NASH</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

